LH | Jotup

The Prelude Network® Names Labcorp Its Preferred Genetic Carrier Screening Lab

Retrieved on:

Friday, March 29, 2024

Genetic testing, Partnership, Physician, Patient, Fertility, Insurance, Inception, FDA, LH, Genetic counseling

HOUSTON, March 29, 2024 /PRNewswire/ -- The Prelude Network® (Prelude), the largest network of fertility clinics in North America, announced today an expansion of its partnership with Labcorp (NYSE: LH), a global leader of innovative diagnostic and biopharma laboratory services, to serve as its Preferred Genetic Carrier Screening Lab.

Key Points:

The expansion of this partnership delivers another level of genetic carrier screening services to Prelude patients, including in-office phlebotomists and patient service centers.
Additionally, Labcorp offers comprehensive genetic counseling, services for provider questions, and complimentary review of carrier screening results for patients.
To improve financial access to genetic carrier screening for the U.S. patient population, Labcorp is contracted with many insurance companies.
"Prelude is excited to offer our patients greater access to best-in-class genetic carrier screening," says Lauri Black, Certified Genetic Counselor and Director of Genetic Services at Inception.

Labcorp to Announce First Quarter Financial Results on April 25, 2024

Retrieved on:

Wednesday, March 27, 2024

Webcast, PIN, LH

BURLINGTON, N.C., March 27, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the first quarter of 2024 before the market opens on Thursday, April 25, 2024.

Key Points:

BURLINGTON, N.C., March 27, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the first quarter of 2024 before the market opens on Thursday, April 25, 2024.
The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website .
The call will be webcast live on the Labcorp Investor Relations website .
To access the webcast recording, visit the Labcorp Investor Relations website .

Labcorp Launches pTau217 Blood Biomarker Test to Accelerate Path to Diagnosis of Alzheimer's Disease and Support Clinical Trials

Retrieved on:

Wednesday, March 20, 2024

Diagnosis, Health, Patient, Research, ATN, Blood, LH, Physician, AFL, Dementia, Medical imaging

BURLINGTON, N.C., March 20, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch and immediate availability of its test to identify the presence or absence of phosphorylated tau 217 (pTau217), a pivotal blood biomarker designed to aid in the diagnosis of Alzheimer's disease and the subsequent monitoring of patients undergoing treatment with new Alzheimer's disease therapies. Labcorp's pTau217 test can be ordered by physicians and used in clinical trials and research by global biopharmaceutical partners.

Key Points:

Labcorp's pTau217 test can be ordered by physicians and used in clinical trials and research by global biopharmaceutical partners.
Alzheimer's disease, the most prevalent form of dementia, poses a significant health challenge globally.
The ATN Profile provides physicians with an accessible and interpretable blood test to assess pathologies associated with Alzheimer's disease and other neurodegenerative conditions, which can help accelerate the path to diagnosis and intervention.
For more information about the pTau217 biomarker and the use of Labcorp's new test in patient care, visit http://www.labcorp.com/alzheimers .

Labcorp Presents New Research Demonstrating Clinical Impact of Precision Diagnostics in Guiding Biomarker-targeted Therapies for Patients with Epithelial Ovarian Cancer

Retrieved on:

Saturday, March 16, 2024

BURLINGTON, N.C., March 16, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today presented the results from two studies at the 2024 SGO Annual Meeting on Women's Cancer. The studies demonstrate the value of biomarker testing in closing testing gaps and guiding targeted therapies for patients with epithelial ovarian cancer (EOC).

Key Points:

The studies demonstrate the value of biomarker testing in closing testing gaps and guiding targeted therapies for patients with epithelial ovarian cancer (EOC).
Labcorp researchers conducted two studies to generate further evidence of the value of comprehensive genomic profiling to drive guideline-compliant testing that enables increased patient access to targeted therapies for improved outcomes.
When combined, the results of BRCA and HRD testing can determine which patients are most likely to benefit from treatment with poly-ADP ribose polymerase (PARP) inhibitors.
"This research emphasizes the power of comprehensive biomarker testing in advancing the treatment of ovarian cancer.

EQS-News: JOST reports on highly successful fiscal year 2023 with adjusted EBIT growing by 14% to EUR 141 million and adjusted EBIT margin reaching a new record high of 11.3%

Retrieved on:

Wednesday, March 13, 2024

Acquisition, Sustainability, APA, LH, Adjustment, EUR, History, Consolidated, Agriculture, Lithium

Reported sales in the transport sector increased by 6.0% to EUR 993.4 million in 2023 (2022: EUR 936.9 million).

Key Points:

Reported sales in the transport sector increased by 6.0% to EUR 993.4 million in 2023 (2022: EUR 936.9 million).
In contrast, sales of agricultural components went down by 21.8% nominally to EUR 256.3 million (2022: EUR 327.7 million).
JOST succeeded in improving adjusted EBIT in Europe by 10.5% year-over-year to EUR 46.2 million in 2023 (2022: EUR 41.8 million).
Oliver Gantzert, Chief Financial Officer of JOST Werke SE, said: “JOST generated a record operating result in 2023 with adjusted EBIT of EUR 140.8 million and an adjusted EBIT margin of 11.3%.

Diagnostics Industry Leader Gary Huff Appointed to Biomerica Strategic Advisory Board

Retrieved on:

Wednesday, February 21, 2024

SAB, FDA, LH, Growth, Sale, HP, Commerce, Labcorp, Central Waqf Council, Workforce, IBS, Management

IRVINE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, proudly announces the appointment of Gary Huff to its Strategic Advisory Board (SAB).

Key Points:

IRVINE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, proudly announces the appointment of Gary Huff to its Strategic Advisory Board (SAB).
Mr. Huff, former CEO of Diagnostics at Laboratory Corporation of America Holdings, “LabCorp” (NYSE: LH), brings extensive expertise to collaborate with Jack Kenny, Chairman of Biomerica, and Zack Irani, CEO of Biomerica, in driving expansion of the inFoods® IBS product.
Most recently, Mr. Huff served as the CEO of LabCorp Diagnostics, overseeing one of the world’s largest diagnostics clinical laboratories, boasting $7B in annual revenues, over 2,000 locations, and a workforce of 36,000 employees.
Zack Irani, CEO of Biomerica, expressed confidence in Mr. Huff’s appointment, stating, “Gary's remarkable career in healthcare and clinical laboratories, particularly as LabCorp’s Diagnostics CEO, showcases his exceptional abilities.

Opengear Launches Enhanced Technical Certification Program

Retrieved on:

Thursday, February 22, 2024

View the full release here: https://www.businesswire.com/news/home/20240221739136/en/

Key Points:

View the full release here: https://www.businesswire.com/news/home/20240221739136/en/
Opengear launches its enhanced Technical Certification Program, providing technical professionals with the knowledge and expertise required to effectively navigate and manage complex network infrastructures.
Features and benefits of the Opengear Technical Certification Program include:
Empowerment and Expertise: Equips professionals with the technical education and expertise needed to address the evolving demands of network management using Opengear solutions.
“Designed exclusively for the technical talents within our channel community, Opengear’s Technical Certification Program is more than just training; it's a commitment to elevating technical excellence,” said Dan Baxter, Director, Sales Engineering, Americas at Opengear.
This program provides our channel technical community with technical resources and the certification they deserve, fostering expertise that benefits both their personal growth and the success of the entire team.”
Members or our channel organizations can register for the Opengear Technical Certification Program by logging into the Partner Portal at https://partners.opengear.com and accessing the training section.

Labcorp Launches Weight Loss Management Testing Solutions

Retrieved on:

Thursday, March 7, 2024

Liver, Physician, Obesity, Cardiovascular disease, LH, Weight loss, Vitamin, Micronutrient, Stroke, Risk, Bariatric surgery, Type 2 diabetes, Health, Type 2, Clinical trial, CDC, Kaiser Family Foundation, Weight management, Dietary supplement

BURLINGTON, N.C., March 7, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the introduction of its Weight Loss Management portfolio. The new offering features educational resources and convenient testing solutions, equipping individuals and their physicians with baseline and ongoing health indicators to inform treatment options, including lifestyle modifications, Glucagon-like peptide-1 (GLP-1) medications or bariatric surgery.

Key Points:

GLP-1 medications for weight loss and diabetes management are also dramatically changing the weight management landscape.
The Weight Management Tracking Test assesses average blood sugar and lipid levels to monitor metabolic health as an individual progresses along the weight loss journey.
"The introduction of GLP-1s and other weight loss treatments has increased interest from individuals and their doctors seeking solutions for effective weight management.
"Our Weight Loss Management offering simplifies the process of obtaining baseline measurements and tracking health progress to empower informed conversations about weight loss between individuals and their doctors."

Mira Introduces First Nationwide Sex Hormones Awareness Week to Close the Knowledge Gap About Female Hormones

Retrieved on:

Monday, February 19, 2024

SAN, Collection, Woman, Menstrual cycle, Hormone, LH, Female, Femtech, Society, Health, Attention, Women's health, Diagnosis, Menopause, Public, Research, Beginners, Birth control

SAN FRANCISCO, Feb. 19, 2024 /PRNewswire/ -- Mira, a hormonal health company providing integrative care and hormonal testing for women, announced the first nationwide Sex Hormones Awareness Week, set to take place from February 18th to February 24th, 2024. With this initiative, Mira seeks to educate people about their sex hormones so that they can make informed decisions about their health.

Key Points:

With this initiative, Mira seeks to educate people about their sex hormones so that they can make informed decisions about their health.
This annual initiative is set to raise public awareness and bridge the gap about female hormonal health.
In light of Sex Hormones Awareness Week, the company released a study on how sex hormones affect mood and well-being .
For more information about Sex Hormones Awareness Week, visit the link https://www.miracare.com/awareness-week/ .

Climate transition risk in the banking sector: what can prudential regulation do?

Retrieved on:

Saturday, February 17, 2024

Working, RWE, Workshop, N2O, Climate, DD, Policy, CES, Macroeconomics, Research Papers in Economics, University, Deleveraging, A.6, PFC, A.7, AWI, Canadian International Council, FRB, Paper, RTF, NX, Household, Economy, Carbon, BTI, Central bank, Classification, Lit, Capital, UH, Government, Parameter, Q54, Credit, Social science, Constantine Dafermos, Simons Foundation, PD, LE, Investment, Part, A.4, AA, A.5, PB, Section 2, Probability, E61, Um, LCI, COVID-19, Coronavirus, Financial regulation, Equation, MCI, Control Engineering (magazine), Environment, CIT, Bank of England, GSF, Directorate, Shock, Relaxation, European Central Bank, DP, Abstract, PTI, DPF, Face, AWB, DSGE, Website, Calibration, Prudential, Ben Bernanke, Climate change, Macroprudential regulation, Money, CRRA, Bank, LH, Methodology, HCI, RF, D58, BK, European Commission, Risk, Biophysical environment, NF3, NCDF, CO2, Acquisition, JEL, Sustainability, American wire gauge, QT, Journal of Financial Stability, BCBS, CSS, Motion, ECB, HFC, RT, CTH, Exercise, Tax, European Parliament, Literature, Qi, Reproduction, LGD, KT, European Green Deal, SF6, Council, DT, FOC, Journal, LG, RSS, EPF, University of Poitiers, UI, ESG, CC, Internalization, CH4, PDF, DTH, RTÉ, Communications satellite

Key Points: